Evidence map›Paper›PMID 37848262›Full record

Observational studyLupus science & medicine2023

COVID-19 prognosis in systemic lupus erythematosus compared with rheumatoid arthritis and spondyloarthritis: results from the CONTROL-19 Study by the Italian Society for Rheumatology.

Chiara Scirocco, Sara Ferrigno, Laura Andreoli, Micaela Fredi, Claudia Lomater, Luca Moroni, Marta Mosca, Bernd Raffeiner, Greta Carrara, Gianpiero Landolfi and 4 more

Open access · goldAbstract readObservational Study
In one paragraph

Observational study in Lupus science & medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 2 pooled it
0.7field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 syntheses or guidelines pooled it, 3 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 9 institutions in 2 countries.

Chiara SciroccoRheumatology Unit, San Camillo-Forlanini Hospital, Rome, Italy cscirocco@scamilloforlanini.rm.it.ORCID 0000-0002-0095-300X
Sara FerrignoRheumatology, Allergology and Clinical Immunology, Department of 'Systems Medicine', University of Rome Tor Vergata, Rome, Italy.
Laura AndreoliRheumatology and Clinical Immunology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.ORCID 0000-0002-9107-3218
Micaela FrediRheumatology and Clinical Immunology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.ORCID 0000-0002-6511-4936
Claudia LomaterRheumatology Unit, Azienda Ospedaliera Ordine Mauriziano di Torino, Turin, Italy.
Luca MoroniUnit of Immunology, Rheumatology, Allergy and Rare Diseases, San Raffaele Hospital IRCCS, Vita-Salute San Raffaele University, Milan, Italy.
Marta MoscaRheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Bernd RaffeinerRheumatology Unit, Department of Medicine, Bolzano Hospital, Bolzano, Italy.
Greta CarraraEpidemiology Research Unit, Italian Society for Rheumatology, Milan, Italy.ORCID 0000-0001-9752-2275
Gianpiero LandolfiEpidemiology Research Unit, Italian Society for Rheumatology, Milan, Italy.
Davide RozzaEpidemiology Research Unit, Italian Society for Rheumatology, Milan, Italy.ORCID 0000-0003-2648-742X
Anna ZanettiEpidemiology Research Unit, Italian Society for Rheumatology, Milan, Italy.ORCID 0000-0001-8408-451X
Carlo Alberto ScirèEpidemiology Research Unit, Italian Society for Rheumatology, Milan, Italy.ORCID 0000-0001-7451-0271
Gian Domenico SebastianiRheumatology Unit, San Camillo-Forlanini Hospital, Rome, Italy.
Società Italiana di Reumatologia · ITAzienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia · ITA. O. Ordine Mauriziano di Torino · ITCarlo Forlanini Hospital · ITNini Hospital · LBOspedale di Bolzano · ITUniversity of Pisa · ITUniversity of Rome Tor Vergata · ITVita-Salute San Raffaele University · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionData concerning SARS-CoV-2 in patients affected by SLE are contradicting.The aim of this study was to investigate disease-related differences in COVID-19 prognosis of patients affected by rheumatic diseases before vaccination; we tested the hypothesis that patients with SLE may have a different outcome compared with those with rheumatoid arthritis (RA) or spondyloarthritis (SPA).

methodsWe analysed data from the national CONTROL-19 Database with a retrospective, observational design, including rheumatic patients affected by COVID-19. The principal outcome measure was hospitalisation with death or mechanical ventilation. Differences between SLE, RA and SPA were analysed by univariable and multivariable logistic regression models.

resultsWe included 103 patients with SLE (88.2% female, mean age 48.9 years, 50.4% active disease), 524 patients with RA (74.4% female, mean age 60.6 years, 59.7% active disease) and 486 patients with SPA (58.1% female, mean age 53.2 years, 58% active disease).Outcome prevalence was not different between patients with SLE and those with RA (SLE 24.5%, RA 25.6%), while patients with SPA showed a more favourable outcome compared with those with SLE (SPA 15.9%); data from the multivariable analysis confirmed this result.In SLE, age >65 years (OR 17.3, CI 5.51 to 63.16, p<0.001), hypertension (OR 6.2, CI 2.37 to 17.04, p<0.001) and prednisone (PDN) use (OR 3.8, CI 1.43 to 11.39, p=0.01) were associated with severe outcomes, whereas hydroxychloroquine use was found to be protective (OR 0.3, CI 0.14 to 0.91, p=0.03).

conclusionOur data suggest that patients with SLE and RA do not show a different COVID-19 outcome, while patients with SPA have a more favourable disease course compared with those with SLE. Risk of hospitalisation with ventilation or death was associated with age >65 years, hypertension and PDN use in patients with SLE.

Indexed as

Arthritis, RheumatoidCOVID-19HypertensionLupus Erythematosus, SystemicRheumatologySpondylarthritisAgedFemaleHumansMaleMiddle AgedPrednisonePrognosisRetrospective StudiesSARS-CoV-2Prednisoneautoimmune diseasesCOVID-19lupus erythematosus, systemic

Identifiers

PMID37848262
PMCPMC10582885
OpenAlexW4387711214

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.